EVerZom raises €10 million to advance exosome biotherapies and scale GMP production

French biotechnology company EVerZom announced the closing of a 10 million euro fundraising round on 8 October 2025. Investors include Capital Grand Est, the European Innovation Council Fund, Sorbonne Venture, Paris Business Angels, the Capital Cell platform and several family offices. The cash injection is earmarked to launch the company’s first clinical trial of EVerGel in 2026, expand indications and to industrialize a GMP-compliant exosome production platform.

What the company claims to have built and why it matters

EVerZom positions itself as a developer of exosome based therapies for regenerative medicine. The company says it has created a patented, standardised and scalable process for producing extracellular vesicles or EVs. The platform is said to cover the entire value chain from cell sourcing through exosome generation and loading to formulation. The firm aims to both progress proprietary therapeutic candidates and offer co-development partnerships with pharmaceutical companies.

ACROBAT project and validation of scale up

EVerZom led a project called ACROBAT that received financing in 2022 via the EIC Accelerator Blended Finance scheme. The project aimed to validate the company’s EV manufacturing platform and to advance scale up towards commercial batch production. The company says ACROBAT supported platform validation and the process used to scale production for human use.

EVerGel, the lead programme and clinical plans

EVerZom’s lead clinical programme, EVerGel, pairs mesenchymal stem cell derived exosomes with a biocompatible hydrogel. The formulation is intended to increase local retention of exosomes at the lesion site, with the objective of promoting tissue repair and durable fistula healing. The company plans to start first in human trials in 2026, targeting complex perianal fistulas in Crohn’s disease.

EVerZom reports strong preclinical efficacy. In an animal model of fistulas, EVerGel reportedly achieved complete healing in 87.5 percent of cases at four weeks, compared with 12.5 percent in the control group. These results are notable but should be interpreted with caution because animal models often fail to predict human outcomes in regenerative medicine.

Funding, investors and intended use of proceeds

EVerZom’s CEO Jeanne Volatron framed the round as a decisive milestone toward clinical proof of concept and building an industrial and partnership platform for a new therapeutic class. The EIC Fund board chair praised the blended finance model as attractive to promising European companies. Those comments echo a broader EU policy goal of retaining biotech scale ups within Europe by combining grant and equity support.

Pipeline beyond EVerGel

Beyond EVerGel, EVerZom is developing Eviv, a preclinical candidate for Acute on Chronic Liver Failure, an area with few treatment options aside from transplantation. The company also lists exploratory projects in ophthalmology, regenerative medicine and non pharmaceutical uses such as cosmetics and veterinary applications. EVerZom plans to expand reach through co development partnerships with larger pharmaceutical companies interested in exosome modalities.

Technical and regulatory risks to watch

While the announcement marks meaningful progress, translating exosome science into approved therapies faces multiple hurdles. Manufacturing reproducibility, clear definitions of product identity, mechanism of action and potency assays remain unresolved across the field. Regulatory agencies are still developing harmonised frameworks for extracellular vesicle products, which can slow clinical development and add costs. The comparison with cell therapies is attractive but exosomes will need to demonstrate clear advantages in safety, efficacy, cost and manufacturability to secure clinical adoption.

Other risks include intellectual property freedom to operate given a crowded patent landscape, long lead times for scaling GMP manufacturing equipment and staff, and the frequent gap between promising animal data and human clinical outcomes. Market access and reimbursement will be decisive if the therapy reaches the clinic, particularly for indications where alternative therapies exist or where the population is relatively small.

Why EIC support and European backing matter

EVerZom’s development to date illustrates the role of European innovation instruments in supporting translational biotech. EIC financing and related national support frequently combine research grants, scale up funding and investment capital which can help de risk early stage development. That support matters in sectors such as advanced therapies where capital intensiveness and regulatory complexity deter private investors.

Assessment and outlook

The €10 million round gives EVerZom runway to enter the clinic and to continue industrialising an exosome platform that the company says is patent protected and validated under the ACROBAT project. These are important steps but the path ahead is uncertain. Clinical proof is required to move beyond preclinical excitement. Success will depend on the robustness of manufacturing scale up, regulatory clarity, clinical safety and efficacy, and later on commercial and reimbursement strategies. If EVerZom can navigate these hurdles it may establish a foothold in an emerging therapeutic category. Observers should expect incremental data releases, regulatory interactions and potential partnerships to be the next meaningful milestones.

EVerZom was founded in 2019 and is a laureate of the EIC Accelerator programme. Interested readers can find further project information in the Horizon Europe database and on EVerZom’s project website. The information presented here summarises the company announcement and places it in the broader context of translational biotech in Europe.